urapidil

Also Known As:

6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil; Ebrantil; urapidil monohydrochloride; urapidil, 2,3-(14)C2-labeled; urapidil, 5-(14)C-labeled; 6-((3-(4- (2-methoxyphenyl)-1-piperazinyl)propyl)amino)- 1,3-dimethyl-2,4(1H,3H)-pyrimidinedione

Networked: 271 relevant articles (35 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - urapidil: 271

Experts

1.	Ren, Chunguang: 3 articles (08/2019 - 01/2016)
2.	Zhang, Zongwang: 3 articles (08/2019 - 01/2016)
3.	Fu, Yan: 3 articles (01/2017 - 08/2015)
4.	Qin, Jian: 3 articles (01/2017 - 08/2015)
5.	Yang, Wei: 3 articles (01/2017 - 08/2015)
6.	Auger, Cyril: 2 articles (10/2019 - 05/2016)
7.	Bopp, Claire: 2 articles (10/2019 - 05/2016)
8.	Diemunsch, Pierre: 2 articles (10/2019 - 05/2016)
9.	Xu, Guangjun: 2 articles (08/2019 - 01/2019)
10.	Hua, Qi: 2 articles (01/2017 - 08/2015)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/1995 - "The beneficial effects of urapidil on hemorheology could add to its therapeutic effects in the treatment of arterial hypertension." 07/01/1993 - "Urapidil demonstrated to be effective and safe in the treatment of patients with mild and moderate arterial hypertension, showing good control of BP levels, without changing the laboratory parameters." 01/01/1988 - "Urapidil, a new alpha 1-adrenoceptor blocking drug, has been shown to be effective in the treatment of hypertension. " 06/01/1990 - "It seems that urapidil may be useful in the treatment of hypertension in dialysed patients. " 10/01/2000 - "[Efficacy of a single dose of urapidil for preventing arterial hypertension during the pre-bypass period in coronary surgery]."
2.	Hypertensive Crisis 01/01/2018 - "We studied patients with hypertensive emergencies before and 4 h after BP lowering by urapidil (n = 12) and studied the release of EMPs due to mechanical endothelial injury after coronary angiography (n = 10). " 10/01/2015 - "Urapidil is more efficient in hypertensive urgency treatment, since the decrease of middle artery pressure (MAP) in the group treated with urapidil was statistically significant (p<0,001). " 01/01/2014 - "The review considers the possibility of using parenteral urapidil for treatment of hypertensive crises. " 01/01/2013 - "[Place of urapidil in the treatment of hypertensive crises from the standpoint of clinical pharmacology and evidence-based medicine]." 01/01/2012 - "[Hypertensive crisis in cardiology: place of urapidil]."
3.	Essential Hypertension 01/01/1988 - "Efficacy of once-daily urapidil treatment in mild or moderate essential hypertension assessed by ambulatory 24-hour blood pressure monitoring." 01/01/1988 - "Efficacy of urapidil in the management of essential hypertension. " 09/22/1990 - "In patients with essential hypertension, forearm, renal and splanchnic flows were shown to increase and vascular resistance to decrease significantly after an acute intravenous doses of urapidil. " 08/15/1989 - "In patients with essential hypertension forearm, renal and splanchnic flow were shown to increase and vascular resistance to decrease significantly after acute intravenous doses of urapidil. " 01/01/1988 - "The blood pressure-lowering effect and tolerability of urapidil 120 mg once daily versus urapidil 60 mg twice daily was compared in 36 outpatients with newly diagnosed mild to moderate essential hypertension. "
4.	Heart Failure 01/01/2019 - "The application of urapidil for treating hypertensive patients with acute heart failure in the emergency department remains controversial. " 01/01/2017 - "Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial." 08/01/2015 - "Both NG and urapidil significantly reduced FPG levels in multifactor heart failure patients with DM. " 01/01/1988 - "Ten normotensive patients with severe congestive heart failure were given Urapidil 25 mg i.v. twice in 15 min and the haemodynamic effects were measured. " 01/01/1988 - "In congestive heart failure, the acute administration of urapidil increases cardiac index and lowers mean pulmonary artery wedge pressure and systemic vascular resistance by about 30%. "
5.	Tachycardia (Tachyarrhythmias) 12/01/1989 - "Urapidil by itself does not impair the performance of the ischaemic myocardium, but might be beneficial in decreasing the heart rate or suppressing reflex tachycardia during reduction of the afterload." 05/01/1998 - "Urapidil works mainly by antagonizing postsynaptic alpha-1-adrenergic receptors and stimulating 5-HT1A receptors, a double mechanism that provides vasodilation with moderate decrease in blood pressure without reflex tachycardia. " 06/01/1994 - "Reduced arterial pressure, systemic vascular resistance and preload after urapidil 0.4 mg kg-1 i.v., associated with lack of prolonged tachycardia and preserved global left ventricular performance, may have obvious clinical implications in anaesthesia." 01/01/1994 - "We started i.v. treatment with urapidil at a diastolic blood pressure of more than 100 mm Hg. We observed a declining blood pressure in all cases without any tachycardia or serious side effects. " 01/01/1990 - "This component is probably additive to the peripheral effect, and is also the background to the lack of reflex tachycardia seen with urapidil. "

Related Drugs and Biologics

1.	Antihypertensive Agents (Antihypertensives)
2.	Nifedipine (Adalat)
3.	Nitroprusside (Sodium Nitroprusside)
4.	Nitroglycerin (Dynamite)
5.	urapidil
6.	Captopril (Capoten)
7.	Clonidine (ST 155)
8.	Dihydralazine
9.	Hydrochlorothiazide (Esidrix)
10.	Prazosin (Minipress)

Related Therapies and Procedures

1.	Extracorporeal Circulation
2.	Therapeutics
3.	Resuscitation
4.	Intravenous Administration
5.	Controlled Hypotension